Lipocalyx GmbH out of Halle, Germany, today reports closing of a € 0.6M financing round. Funds were provided to support the development of pharmaceutical applications of the companies’ Viromer® technology for the delivery of mRNA or siRNA therapeutics. The IBG Sachsen-Anhalt and founder Dr. Panzner were investors to the round.
Dr. Angelika Vlachou, investment manager at IBG, says: “Lipocalyx is one of the most creative companies in our portfolio. Quickly after having established their reagent business, the team was able to demonstrate the delivery of therapeutic payloads with their Viromer® technology. We together with the founder provide additional funds to develop and build this technology.”
Dr. Panzner, Founder and CEO, comments: “This technology is a true breakthrough in the field, it is orthogonal to established methods and has delivered prompt results. The field of genomic medicines has a great appetite for solutions like this, so we are operating well in sync with the markets.”